Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy

被引:57
|
作者
Munir, WM
Pulido, JS
Sharma, MC
Buerk, BM
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA
关键词
intravitreal steroids; pars plana vitrectomy; proliferative diabetic retinopathy; proliferative vitreoretinopathy; triamcinolone acetonide;
D O I
10.1016/S0008-4182(05)80052-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: We present a retrospective evaluation of the clinical outcome and complications associated with intravitreal injection of unaltered triamcinolone acetonide in conjunction with pars plana vitrectomy and silicone oil injection for the treatment of complicated proliferative diabetic retinopathy with tractional retinal detachment and severe proliferative vitreoretinopathy. Methods: Thirteen eyes of 12 consecutive patients were identified from a computerized patient database. All eyes were operated on by the same surgeon and received 4 mg of unaltered, commercially available triamcinolone acetonide intravitreally, before silicone oil injection. The patients were followed for a mean of 4.7 months (range 1-15 months), and demographic as well as pertinent preoperative and postoperative clinical information was gathered. Results: At the last follow-up visit, vision had improved in 4 eyes, remained stable in 5 eyes, and worsened in 4 eyes. The retina was attached at the end of follow-up in 10 of the 13 eyes. Eight of the 13 eyes did not show any clinical signs of reproliferation or redetachment during the course of follow-up. The mean intraocular pressure did not increase (preoperative value was 10.8 6.22 mm Hg with a range of 0-22 mm Hg; at last follow-up, mean pressure was 9.6 +/- 3.86 mm Hg with a cumulative postoperative range of 0-26 mm Hg). Steroid crystals were visible at 1 month postoperatively in 3 eyes and did not hinder fundus examination significantly. Interpretation: The intravitreal injection of low-dose, unaltered triamcinolone acetonide in the setting of pars plana vitrectomy and silicone oil injection for the treatment of proliferative vitreoretinopathy and complicated proliferative diabetic retinopathy appears to be well tolerated. Further controlled study is needed to clearly define the potential beneficial effects of intravitreal steroids in these 2 disease processes.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [1] Intravitreal triamcinolone acetonide for the treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy
    Munir, WM
    Pulido, JS
    Sharma, MC
    Buerk, B
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U768 - U768
  • [2] Intravitreal triamcinolone as an adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy
    Pognuz, DR
    Polito, A
    Monaco, P
    Dimastrogiovanni, A
    Lanzetta, P
    Bandello, F
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [3] Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy
    Bandello, F
    Pognuz, DR
    Pirracchio, A
    Polito, A
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2004, 242 (12) : 1024 - 1027
  • [4] Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy
    Francesco Bandello
    Derri Roman Pognuz
    Angelo Pirracchio
    Antonio Polito
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242 : 1024 - 1027
  • [5] Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy
    Abu El-Asrar, Ahmed M.
    Struyf, Sofie
    Kangave, Dustan
    Geboes, Karel
    Van Damme, Jo
    EUROPEAN CYTOKINE NETWORK, 2006, 17 (03) : 155 - 165
  • [6] CYTOKINES IN PROLIFERATIVE DIABETIC-RETINOPATHY AND PROLIFERATIVE VITREORETINOPATHY
    ELNER, SG
    ELNER, VM
    JAFFE, GJ
    STUART, A
    KUNKEL, SL
    STRIETER, RM
    CURRENT EYE RESEARCH, 1995, 14 (11) : 1045 - 1053
  • [7] Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema
    Kaderli B.
    Avci R.
    Gelisken O.
    Yucel A.Â.
    International Ophthalmology, 2005, 26 (6) : 207 - 214
  • [8] Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage
    Spaide, Richard F.
    Fisher, Yale L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03): : 275 - 278
  • [9] Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema
    Kumar, Vinod
    Ghosh, Basudeb
    Goel, Neha
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (01) : 171 - 171
  • [10] The expression of mRNA in the vitreous of proliferative diabetic retinopathy and proliferative vitreoretinopathy
    Kwak, H
    Yu, SY
    Nam, WH
    Kim, JS
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U85 - U85